Deciphera Pharmaceuticals (DCPH)
(Delayed Data from NSDQ)
$14.67 USD
+0.44 (3.09%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $14.69 +0.02 (0.14%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Income Statements
Fiscal Year end for Deciphera Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 163 | 134 | 96 | 42 | 25 |
Cost Of Goods | 4 | 9 | 3 | 0 | 0 |
Gross Profit | 160 | 125 | 93 | 42 | 25 |
Selling & Adminstrative & Depr. & Amort Expenses | 371 | 308 | 393 | 313 | 226 |
Income After Depreciation & Amortization | -211 | -183 | -300 | -271 | -201 |
Non-Operating Income | 16 | 5 | 0 | 5 | 9 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -195 | -178 | -300 | -266 | -192 |
Income Taxes | 0 | 1 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -195 | -179 | -300 | -266 | -192 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -195 | -179 | -300 | -266 | -192 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -209 | -180 | -297 | -269 | -200 |
Depreciation & Amortization (Cash Flow) | 2 | 3 | 3 | 2 | 1 |
Income After Depreciation & Amortization | -211 | -183 | -300 | -271 | -201 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 85.06 | 75.50 | 58.08 | 55.78 | 42.87 |
Diluted EPS Before Non-Recurring Items | -2.29 | -2.37 | -5.16 | -4.78 | -4.48 |
Diluted Net EPS (GAAP) | -2.29 | -2.37 | -5.16 | -4.78 | -4.48 |
Fiscal Year end for Deciphera Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 48.29 | 43.31 | 38.30 | 33.45 |
Cost Of Goods | NA | 1.79 | 1.29 | 0.17 | 0.49 |
Gross Profit | NA | 46.51 | 42.03 | 38.13 | 32.96 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 97.75 | 95.71 | 90.91 | 86.22 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -51.24 | -53.68 | -52.78 | -53.26 |
Non-Operating Income | NA | 4.48 | 4.11 | 4.21 | 3.65 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -46.76 | -49.58 | -48.56 | -49.61 |
Income Taxes | NA | 0.43 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -47.19 | -49.58 | -48.56 | -49.61 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -47.19 | -49.58 | -48.56 | -49.61 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 86.70 | 85.79 | 85.02 | 82.68 |
Diluted EPS Before Non-Recurring Items | NA | -0.54 | -0.58 | -0.57 | -0.60 |
Diluted Net EPS (GAAP) | NA | -0.54 | -0.58 | -0.57 | -0.60 |